Clinical trial
Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes
NCT00422487 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00422487 |
|---|---|
| Title | Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes |
| Official title | Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of MBX-2044 to Evaluate the Multiple-dose Pharmacokinetics, Safety and Tolerability When Administered Orally in Patients With Type 2 Diabetes |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | MBX-2044, Placebo for MBX-2044 |
| Enrollment | 60 |
| Start date | Oct 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Jan 17, 2007 |
| Last update posted | May 1, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: